We have presented a mechanism that connects AHCY activity, DNA damage and cell cycle regulation through adenosine levels and draw two major conclusions, which may lead to a refinement of therapeutic procedures for liver cancer as a result of AHCY malfunction and a potentially new approach for targeted cancer therapy based on adenosine depletion. The gene discussed is AHCY; the disease is cancer.